Updates are available Correction dated 2021-05-06
Click to view Correction: https://doi.org/10.1038/s41388-021-01805-6
Updates are available Correction dated 2021-02-09
Click to view Correction: https://doi.org/10.1038/s41388-021-01640-9
-
Authors
Zhu, Yezi
Dalrymple, Susan L.
Coleman, Ilsa
Zheng, S. Lilly
Xu, Jianfeng http://orcid.org/0000-0002-1343-8752
Hooper, Jody E.
Antonarakis, Emmanuel S.
De Marzo, Angelo M.
Meeker, Alan K.
Nelson, Peter S.
Isaacs, William B.
Denmeade, Samuel R.
Luo, Jun
Brennen, W. Nathaniel http://orcid.org/0000-0001-9807-7433
Isaacs, John T. http://orcid.org/0000-0002-3854-4658
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-18-2-0015, W81XWH-17-1-0528)
U.S. Department of Health & Human Services | National Institutes of Health (P50 CA058236)
- License Information
-
More Information
Article History
Received: 29 May 2020
Revised: 19 August 2020
Accepted: 15 September 2020
First Online: 28 September 2020
Change Date: 9 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41388-021-01640-9
Change Date: 6 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41388-021-01805-6
Compliance with ethical standards
:
: ESA is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, AstraZeneca, Bristol Myers Squibb, Bayer, Clovis, and Merck; has received research funding (to his institution) from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Bristol Myers Squibb, AstraZeneca, Clovis, and Merck. ESA and JL are co-inventors of an AR-V7 biomarker technology that has been licensed to Qiagen.
